4,069 Shares in Novartis AG (NYSE:NVS) Purchased by Nwam LLC

Nwam LLC purchased a new position in Novartis AG (NYSE:NVS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,069 shares of the company’s stock, valued at approximately $468,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James & Associates increased its stake in shares of Novartis by 1.3% during the second quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock valued at $57,127,000 after purchasing an additional 6,767 shares in the last quarter. Manning & Napier Advisors LLC purchased a new stake in shares of Novartis during the second quarter valued at approximately $15,044,000. Integral Health Asset Management LLC grew its holdings in shares of Novartis by 33.3% during the second quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after buying an additional 75,000 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new stake in shares of Novartis during the second quarter valued at approximately $854,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Novartis by 115.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after purchasing an additional 124,111 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on NVS shares. The Goldman Sachs Group restated a “neutral” rating and issued a $121.00 target price (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Jefferies Financial Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Bank of America downgraded shares of Novartis from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $135.00 to $130.00 in a research report on Wednesday, September 11th. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Finally, Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Price Performance

NVS stock opened at $104.28 on Monday. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $111.87 and a 200 day moving average price of $110.20. The stock has a market cap of $213.15 billion, a PE ratio of 12.11, a P/E/G ratio of 1.49 and a beta of 0.58.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the previous year, the company earned $1.74 EPS. Equities research analysts anticipate that Novartis AG will post 7.66 earnings per share for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.